Inspire Medical Systems (NYSE:INSP) Rating Lowered to Equal Weight at Wells Fargo & Company

Inspire Medical Systems (NYSE:INSP) was downgraded by investment analysts at Wells Fargo & Company from an “overweight” rating to an “equal weight” rating in a research note issued on Thursday, MarketBeat.com reports. They presently have a $70.00 target price on the stock, down from their prior target price of $145.00. Wells Fargo & Company‘s price objective indicates a potential upside of 17.09% from the company’s current price.

Several other research firms have also recently issued reports on INSP. KeyCorp reissued a “sector weight” rating on shares of Inspire Medical Systems in a research note on Tuesday, November 4th. Morgan Stanley reissued an “equal weight” rating and set a $130.00 price objective (up from $105.00) on shares of Inspire Medical Systems in a research report on Tuesday, December 2nd. Oppenheimer lowered shares of Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a report on Thursday, January 22nd. Stifel Nicolaus set a $95.00 target price on shares of Inspire Medical Systems in a research report on Thursday. Finally, Jefferies Financial Group reduced their price target on shares of Inspire Medical Systems from $81.00 to $66.00 and set a “hold” rating on the stock in a research report on Thursday. Five research analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $108.94.

Inspire Medical Systems Stock Up 0.2%

Shares of INSP opened at $59.78 on Thursday. The stock has a market capitalization of $1.74 billion, a P/E ratio of 12.00, a PEG ratio of 6.34 and a beta of 0.74. Inspire Medical Systems has a twelve month low of $53.11 and a twelve month high of $197.75. The firm has a fifty day simple moving average of $92.88 and a two-hundred day simple moving average of $90.99.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 EPS for the quarter, beating the consensus estimate of $0.69 by $0.96. The firm had revenue of $269.08 million during the quarter, compared to the consensus estimate of $264.02 million. Inspire Medical Systems had a net margin of 15.95% and a return on equity of 10.96%. The company’s quarterly revenue was up 12.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.15 earnings per share. Sell-side analysts expect that Inspire Medical Systems will post 2.16 EPS for the current fiscal year.

Insider Transactions at Inspire Medical Systems

In related news, Director Shawn Mccormick sold 2,000 shares of the business’s stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $127.48, for a total transaction of $254,960.00. Following the sale, the director owned 26,046 shares of the company’s stock, valued at $3,320,344.08. The trade was a 7.13% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.10% of the stock is currently owned by company insiders.

Institutional Trading of Inspire Medical Systems

Several institutional investors have recently bought and sold shares of INSP. Dragoneer Investment Group LLC raised its holdings in Inspire Medical Systems by 81.4% in the second quarter. Dragoneer Investment Group LLC now owns 2,354,411 shares of the company’s stock worth $305,532,000 after buying an additional 1,056,808 shares during the last quarter. Wasatch Advisors LP raised its holdings in Inspire Medical Systems by 7.2% in the 2nd quarter. Wasatch Advisors LP now owns 1,634,395 shares of the company’s stock worth $212,095,000 after acquiring an additional 110,288 shares during the last quarter. William Blair Investment Management LLC raised its holdings in Inspire Medical Systems by 68.7% in the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company’s stock worth $96,280,000 after acquiring an additional 528,404 shares during the last quarter. Morgan Stanley lifted its position in Inspire Medical Systems by 179.5% in the 4th quarter. Morgan Stanley now owns 1,259,762 shares of the company’s stock valued at $116,188,000 after acquiring an additional 809,121 shares in the last quarter. Finally, Deerfield Management Company L.P. boosted its stake in Inspire Medical Systems by 648.4% during the 3rd quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company’s stock valued at $77,739,000 after purchasing an additional 907,694 shares during the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q4 beat: INSP reported $1.65 EPS vs. $0.69 expected and revenue of ~$269M, with expanded gross margins — a near-term operational positive. Zacks: INSP Beats Q4 Estimates
• Positive Sentiment: Some firms remain constructive at reduced targets — Mizuho and Piper Sandler kept outperform/overweight stances after lowering PTs, signaling there’s still perceived upside if reimbursement issues resolve. The Fly: Mizuho PT Cut
• Neutral Sentiment: Earnings call materials and transcript are available for detailed read-through (management commentary on coding, reimbursement and 2026 guide are key). Review to judge whether guidance risks are transitory. Seeking Alpha: Q4 Earnings Call Transcript
• Negative Sentiment: Management issued a 2026 revenue outlook of $950M–$1B and flagged a coding change plus reimbursement headwinds — the primary catalyst for the selloff risk and weaker forward expectations. MSN: 2026 Revenue Outlook & Coding Change
• Negative Sentiment: Multiple analyst downgrades and price-target cuts (Wells Fargo, Baird, Jefferies, Truist and others) followed the guidance and reimbursement concerns, increasing near-term selling pressure. Investing.com: Baird, Wells Fargo Cuts
• Negative Sentiment: The stock already experienced an earlier ~8% intraday decline after the coding/guidance news, showing how sensitive the market is to reimbursement updates. Investing.com: Shares Slide 8%

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.